Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Aligos Therapeutics Q3 net loss narrows on lower R&D costs

By Reuters News


Overview

  • US biotech firm's Q3 net loss and loss per share both beat analyst expectations

  • Operating expenses fell yr/yr, mainly due to lower R&D costs for hepatitis B trial


Outlook

  • Aligos anticipates cash and investments will fund operations into Q1 2027


Result Drivers

  • LOWER R&D COSTS - Co said decrease in R&D expenses was mainly due to reduced third-party costs for pevifoscorvir sodium Phase 2 trial

  • TRIAL ENROLLMENT COMPLETE - Co said enrollment for Phase 2 B-SUPREME study of pevifoscorvir sodium is complete


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

Beat

$2.09

$2.17 (7 Analysts)

Q3 Net Loss

Beat

$21.86 mln

$24.74 mln (7 Analysts)

Q3 Income From Operations

Beat

-$21.89 mln

-$25.33 mln (7 Analysts)

Q3 Pretax Loss

Beat

$21.53 mln

$24.73 mln (7 Analysts)

Q3 Operating Expenses

$24.76 mln


Reuters Recommended Reads

  • Nov 5 - Janux Therapeutics Q3 net loss narrows on lower R&D expenses

  • Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

  • Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.